← Home / Relay Therapeutics, Inc. (RLAY)
Stock Analysis

Relay Therapeutics, Inc. (RLAY)

RLAY
RLAY · Healthcare • Biotechnology
18.99 +2.59%
Track RLAY in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when RLAY price is:
52W Range Position
89%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-09-03 21:43 UTC
WOI Investment Thesis
Mixed
Current market structure would strengthen above 20.99. Holding above 17.71 preserves the current price structure.
⚖️
✓
Fundamentals
Weak / Negative / Pressured / Strong
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
17.71
↗
Break Above
No setup-specific trigger is available; nearest structural resistance is shown.
20.99
🎯
Next Objective
No defined objective is currently available for the primary technical setup.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
6
●
Financial Results
HIGH
RLAY reports financial results
(the “Company”) previously entered into a common stock sales agreement (the “Original Sales Agreement”), dated August 6, 2024, with TD Securities (USA) LLC (“TD Cowen” or the “Sales Agent”), relating to shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offerin...
8-K Filing • SEC EDGAR
AUG
6
↗
Equity Offering / Capital Raise
HIGH
RLAY equity financing update
(the “Company”) previously entered into a common stock sales agreement (the “Original Sales Agreement”), dated August 6, 2024, with TD Securities (USA) LLC (“TD Cowen” or the “Sales Agent”), relating to shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offerin...
8-K Filing • SEC EDGAR
MAY
21
●
Material Agreement
MEDIUM
RLAY material agreement
On May 20, 2026, Relay Therapeutics, Inc.
8-K Filing • SEC EDGAR
What's Driving RLAY?
• No active technical setup
Momentum is Neutral. No qualified technical setup is currently active.
◆ Business quality is mixed
Revenue growth is weak. Profitability is negative. Cash generation is pressured. Balance-sheet quality is strong.
⚠️ Key risk remains
losing 17.71 would weaken the current structure.
Full Analysis Workspace
Technical Signal
No Active Technical Setup
•
No qualified technical setup is currently active.
RSI(14)
47.3
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 17.71 and resistance around 20.99. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
RLAY — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-09-02
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$4.1B
Company size
EV
$3.2B
Debt-adjusted value
P/B
4.5
Balanced
EV/EBIT
-1.2
Not meaningful
P/FCF
-34.0
Not meaningful
FCF Yield
-2.94%
Cash return
Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
350,000
↘ Weak
📈 Net Income
-83.71M
↘ Negative
🧮 EPS (Basic)
-0.41
↘ Negative
Relay Therapeutics, Inc.
Healthcare • Biotechnology
You Might Also Like